Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-08 10:52 am Purchase | 2024-09-30 | 13G | Celldex Therapeutics, Inc. CLDX | Wellington Management Group LLP | 9,243,599 13.940% | 2,767,038 (+42.72%) | Filing History |
| 2024-02-14 4:17 pm Sale | 2023-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | Point72 Asset Management, L.P. | 2,756,122 5.000% | -866,014 (-23.91%) | Filing History |
| 2024-02-14 12:52 pm Purchase | 2023-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | Kynam Capital Management, LP | 3,005,904 5.500% | 3,005,904 (New Position) | Filing History |
| 2024-02-14 11:48 am Purchase | 2023-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | Eventide Asset Management, LLC | 3,630,013 6.640% | 3,630,013 (New Position) | Filing History |
| 2024-02-14 07:38 am Purchase | 2023-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | RTW Investments, LP | 3,463,201 6.300% | 378,986 (+12.29%) | Filing History |
| 2024-02-13 5:00 pm Purchase | 2023-12-29 | 13G | Celldex Therapeutics, Inc. CLDX | The Vanguard Group | 3,046,331 5.570% | 532,767 (+21.20%) | Filing History |
| 2024-02-13 09:41 am Purchase | 2023-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | Polar Capital Holdings Plc | 3,135,871 5.730% | 3,135,871 (New Position) | Filing History |
| 2024-02-09 08:50 am Sale | 2024-02-08 | 13G | Celldex Therapeutics, Inc. CLDX | FMR LLC | 7,050,409 12.891% | -14,565 (-0.21%) | Filing History |
| 2024-02-08 10:11 am Purchase | 2023-12-29 | 13G | Celldex Therapeutics, Inc. CLDX | Wellington Management Group LLP | 6,476,561 11.840% | 1,695,064 (+35.45%) | Filing History |
| 2024-01-26 5:25 pm Purchase | 2023-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | BlackRock Inc. BLK | 3,675,692 6.700% | 450,976 (+13.98%) | Filing History |
| 2023-11-20 4:15 pm Purchase | 2023-11-10 | 13G | Celldex Therapeutics, Inc. CLDX | Point72 Asset Management, L.P. | 3,622,136 6.600% | 3,622,136 (New Position) | Filing History |
| 2023-05-10 08:54 am Purchase | 2023-04-28 | 13G | Celldex Therapeutics, Inc. CLDX | Wellington Management Group LLP | 4,781,497 10.120% | 133,585 (+2.87%) | Filing History |
| 2023-02-14 1:18 pm Sale | 2022-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | VIKING GLOBAL INVESTORS LP | 0 0.000% | -2,366,385 (Position Closed) | Filing History |
| 2023-02-14 10:08 am Sale | 2022-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | RTW Investments, LP | 3,084,215 6.500% | -837,364 (-21.35%) | Filing History |
| 2023-02-09 11:12 am Purchase | 2022-12-30 | 13G | Celldex Therapeutics, Inc. CLDX | The Vanguard Group | 2,513,564 5.340% | 100,508 (+4.17%) | Filing History |
| 2023-02-09 09:59 am Purchase | 2023-02-09 | 13G | Celldex Therapeutics, Inc. CLDX | FMR LLC | 7,064,974 14.999% | 65,394 (+0.93%) | Filing History |
| 2023-02-06 2:49 pm Purchase | 2022-12-30 | 13G | Celldex Therapeutics, Inc. CLDX | Wellington Management Group LLP | 4,647,912 9.870% | 4,647,912 (New Position) | Filing History |
| 2023-02-01 10:22 am Sale | 2022-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | STATE STREET CORP STT | 2,291,454 4.870% | -76,586 (-3.23%) | Filing History |
| 2023-01-31 5:52 pm Purchase | 2022-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | BlackRock Inc. BLK | 3,224,716 6.800% | 123,686 (+3.99%) | Filing History |
| 2022-06-10 4:15 pm Purchase | 2022-05-31 | 13G | Celldex Therapeutics, Inc. CLDX | VIKING GLOBAL INVESTORS LP | 2,366,385 5.100% | 2,366,385 (New Position) | Filing History |